Data presented at the American Society of Clinical Oncology annual meeting seem likely to shake up the ovarian cancer market. ImmunoGen, Inc.’s Phase III confirmatory MIRASOL trial of its antibody-drug conjugate Elahere (mirvetuximab soravtansine-gynx) supports a shift in treatment paradigms for patients with ovarian cancer resistant to platinum chemotherapy. Meanwhile, Sutro Biopharma, Inc.’s luveltamab tazevibulin presents a potential option for patients with levels of folate receptor alpha (FRα) expression too low to make them eligible for treatment with Elahere.
ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use
The presenter on the MIRASOL study called the data “practice changing,” while the discussant cited Sutro’s STRO-002 as a potential option for patients with low folate receptor alpha expression.
More from ASCO
• By
Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.
• By
The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers.
• By
Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.
• By
US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.
More from Conferences
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.